News
5hon MSN
There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
Instead of helping Mom, she does things to deliberately upset her and raise her blood pressure. Two examples: putting dog ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results